These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 33023950)

  • 21. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.
    Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA
    Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins.
    Zou A; Lambert D; Yeh H; Yasukawa K; Behbod F; Fan F; Cheng N
    BMC Cancer; 2014 Oct; 14():781. PubMed ID: 25344051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
    Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
    Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibroblast growth factor-2, derived from cancer-associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling.
    Suh J; Kim DH; Lee YH; Jang JH; Surh YJ
    Mol Carcinog; 2020 Sep; 59(9):1028-1040. PubMed ID: 32557854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer.
    Seachrist DD; Sizemore ST; Johnson E; Abdul-Karim FW; Weber Bonk KL; Keri RA
    Breast Cancer Res; 2017 Jun; 19(1):66. PubMed ID: 28583174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absence of integrin α3β1 promotes the progression of HER2-driven breast cancer in vivo.
    Ramovs V; Secades P; Song JY; Thijssen B; Kreft M; Sonnenberg A
    Breast Cancer Res; 2019 May; 21(1):63. PubMed ID: 31101121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
    Karakashev SV; Reginato MJ
    Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and functional significance of tumor/stromal ATR expression in breast cancer patients.
    Al-Ansari MM; Al-Saif M; Arafah M; Eldali AM; Tulbah A; Al-Tweigeri T; Semlali A; Khabar KS; Aboussekhra A
    Breast Cancer Res; 2020 May; 22(1):49. PubMed ID: 32414408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential.
    Knudsen ES; Balaji U; Freinkman E; McCue P; Witkiewicz AK
    Oncotarget; 2016 Nov; 7(48):78396-78411. PubMed ID: 27623078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation.
    Yu M; Lin G; Arshadi N; Kalatskaya I; Xue B; Haider S; Nguyen F; Boutros PC; Elson A; Muthuswamy LB; Tonks NK; Muthuswamy SK
    Mol Cell Biol; 2012 Oct; 32(19):3913-24. PubMed ID: 22851698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-124 inhibits cell proliferation and migration by regulating SNAI2 in breast cancer.
    Du S; Li H; Sun X; Li D; Yang Y; Tao Z; Li Q; Liu K
    Oncol Rep; 2016 Dec; 36(6):3259-3266. PubMed ID: 27748910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
    Shen G; Huang H; Zhang A; Zhao T; Hu S; Cheng L; Liu J; Xiao W; Ling B; Wu Q; Song L; Wei W
    Cancer Immunol Immunother; 2011 Mar; 60(3):339-48. PubMed ID: 21086124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Influence of Tumor Stroma on Breast Cancer Subtypes.
    Cid S; Eiro N; Fernández B; Sánchez R; Andicoechea A; Fernández-Muñiz PI; González LO; Vizoso FJ
    Clin Breast Cancer; 2018 Feb; 18(1):e123-e133. PubMed ID: 28927692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
    Prat A; Karginova O; Parker JS; Fan C; He X; Bixby L; Harrell JC; Roman E; Adamo B; Troester M; Perou CM
    Breast Cancer Res Treat; 2013 Nov; 142(2):237-55. PubMed ID: 24162158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers.
    Strong AL; Ohlstein JF; Biagas BA; Rhodes LV; Pei DT; Tucker HA; Llamas C; Bowles AC; Dutreil MF; Zhang S; Gimble JM; Burow ME; Bunnell BA
    Breast Cancer Res; 2015 Aug; 17(1):112. PubMed ID: 26286584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ERBB2 overexpression triggers transient high mechanoactivity of breast tumor cells.
    Martin M; Müller K; Cadenas C; Hermes M; Zink M; Hengstler JG; Käs JA
    Cytoskeleton (Hoboken); 2012 May; 69(5):267-77. PubMed ID: 22407943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. microRNA-33a prevents epithelial-mesenchymal transition, invasion, and metastasis of gastric cancer cells through the Snail/Slug pathway.
    Chen DD; Cheng JT; Chandoo A; Sun XW; Zhang L; Lu MD; Sun WJ; Huang YP
    Am J Physiol Gastrointest Liver Physiol; 2019 Aug; 317(2):G147-G160. PubMed ID: 30943047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CXADR-Mediated Formation of an AKT Inhibitory Signalosome at Tight Junctions Controls Epithelial-Mesenchymal Plasticity in Breast Cancer.
    Nilchian A; Johansson J; Ghalali A; Asanin ST; Santiago A; Rosencrantz O; Sollerbrant K; Vincent CT; Sund M; Stenius U; Fuxe J
    Cancer Res; 2019 Jan; 79(1):47-60. PubMed ID: 30385615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.